A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer

BACKGROUND: Mismatch repair proficient (MMRp) colorectal cancer (CRC) has been refractory to single‐agent programmed cell death protein 1 (PD1) inhibitor therapy. Colon GVAX is an allogeneic, whole‐cell, granulocyte‐macrophage colony‐stimulating factor ‐secreting cellular immunotherapy that induces...

Descripción completa

Detalles Bibliográficos
Autores principales: Yarchoan, Mark, Huang, Chiung‐Yu, Zhu, Qingfeng, Ferguson, Anna K., Durham, Jennifer N., Anders, Robert A., Thompson, Elizabeth D., Rozich, Noah S., Thomas, Dwayne L., Nauroth, Julie M., Rodriguez, Christina, Osipov, Arsen, De Jesus‐Acosta, Ana, Le, Dung T., Murphy, Adrian G., Laheru, Daniel, Donehower, Ross C., Jaffee, Elizabeth M., Zheng, Lei, Azad, Nilofer S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013064/
https://www.ncbi.nlm.nih.gov/pubmed/31876399
http://dx.doi.org/10.1002/cam4.2763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013064/
https://www.ncbi.nlm.nih.gov/pubmed/31876399
http://dx.doi.org/10.1002/cam4.2763

Ejemplares similares